#### Note:

- Forward-looking statements, such as business forecasts, made in these financial statements are based on managements' estimates, assumptions and projections at the time of publication and do not represent a commitment from Ajinomoto Co., Inc. that they will be achieved. A number of factors could cause actual results to differ materially from expectations.
- ■Unaudited figures are included in this material for reference.
- ■Yen amounts presented in these materials are rounded to the nearest hundred million for amounts in billions and truncated for amounts in millions.
- ■In these materials, "-" indicates that an amount has not been recognized, and "0" indicates a fractional amount due to rounding.

#### 1. Financial Statement Overview

		FY ending	6 Months		6 Months		6 Months			
		Mar/14	ended	FY ended	ended	FY ended	ended	FY ended	FY ended	FY ended
		(projected)	Sept/13	Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10	Mar/09
(1) Operating Results										
Net Sales*	M. JPY	1,032,000	487,084	984,967	505,921	1,007,208	604,110	1,015,213		1,190,371
Gross profit	M. JPY	367,500	173,444	384,337	204,298	403,788	206,823	402,978	385,298	357,247
Operating income	M. JPY	68,000		71,232	36,887	72,584	42,594	69,374	64,034	
Ordinary profit	M. JPY	74,000	32,886	77,167	39,257	75,919	44,132	70,499	67,621	25,926
Net income	M. JPY	48,000	22,179	48,373	41,106	41,754	25,715	30,400	16,646	-10,227
Earnings per share	JPY	77.93	35.79	74.35	61.92	61.28	37.52	43.56	23.85	-14.65
Return on equity (ROE)		7.9%		7.8%		6.9%		5.0%	2.8%	-1.7%
Ratio of net income to total assets		4.6%		4.4%		3.8%		2.8%	1.6%	-0.9%
Ratio of operating income to net sales		6.6%	6.1%	7.2%	7.3%	7.2%	7.1%	6.8%	6.5%	3.4%
Ratio of ordinary income to net sales		7.2%	6.8%	7.8%	7.8%	7.5%	7.3%	6.9%	6.9%	2.2%
(2) Statement of Changes in Financial Pos	sition									
Total assets	M. JPY	1,053,300	1,069,118	1,091,741	1,029,838	1,097,057	1,028,210	1,077,418	1,082,238	1,057,786
Net assets	M. JPY	674,400	647,928	691,710	629,442	650,159	614,349	650,291	643,179	618,654
Shareholders' equity	M. JPY	616,100	592,280	635,287	585,962	605,349	574,883	608,191	602,769	585,234
Shareholders' equity ratio		58.5%	55.4%	58.2%	56.9%	55.2%	55.9%	56.4%	55.7%	55.3%
Book value per share	JPY	1,007.40	968.45	1,004.38	903.73	894.58		871.61	863.72	838.51
(3) Summary of Cash Flow Statement										
Net cash provided by operating activities	M. JPY		19,592	88,501	31,949	93,312	37,165	112,716	105,924	
Net cash used in investing activities	M. JPY		-37,401	15,201	-30,416	-41,701	-21,230	-45,882	-63,327	-62,487
Net cash used in financing activities	M. JPY		-22,686	-74,419	-54,368	-37,456	-30,160	-25,893	-18,011	-2,119
Cash and cash equivalents at end of period	M. JPY		142,548	184,770	88,132	146,647	113,291	133,744	95,063	67,790

\*For the coffee and edible oils business and some other businesses, the gross figures for sales and cost of goods sales were recorded in the accounts but from fiscal 2013 this method is scheduled to change by netting off sales and cost of goods sold and recording the net figure in the accounts.

\*Post-reclassification basis from fiscal 2009.

#### 2. Number of Consolidated Subsidiaries/Affiliates

	FY ending	6 Months		6 Months		6 Months			
	Mar/14	ended	FY ended	ended	FY ended	ended	FY ended	FY ended	FY ended
	(projected)	Sept/13	Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10	Mar/09
Consolidated domestic subsidiaries	39	39	38	41	42	41	41	42	45
Consolidated overseas subsidiaries	50	50	48	51	51	53	54	58	58
Sub-Total	89	89	86	92	93	94	95	100	103
Domestic affiliates subject to equity method	6	6	5	5	4	4	4	4	4
Overseas affiliates subject to equity method	6	6	6	6	6	6	6	6	6
Sub-Total	12	12	11	11	10	10	10	10	10
Parent company	1	1	1	1	1	1	1	1	1
Total	102	102	98	104	104	105	106	111	114

3. Change of Number of Consolidated Subsidiaries/Affiliates (from Mar/13 to Sept/13)

	Increase(3)	Increase:	AJINOMOTO NUTRITION FOODS CO,. LTD, Ajinomoto Althea, Inc.,
			Sazonadores del Pacifico C. Ltda.
	Decrease(0)	Decrease:	None
Equity method	Increase(1)	Increase:	AY PHARMACEUTICALS CO., LTD
, ,	morease(1)		
	Decrease(0)	Decrease:	None
	200,000(0)		

4. Foreign Exchange Information

4. I Oreign Exchange into										
		FY ending	6 Months		6 Months		6 Months			
		Mar/14	ended	FY ended	ended	FY ended	ended	FY ended	FY ended	FY ended
		(projected)	Sept/13	Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10	Mar/09
JPY/US Dollar	End of Period	97.8	97.75	94.05	77.60	82.19	76.65	83.15	93.04	98.23
	Average	98.0	98.86	82.91	79.41	79.08	79.75	85.74	92.89	100.71
JPY/Euro	End of Period	131.9	131.87	120.73	100.24	109.80	104.11	117.57	124.92	129.84
	Average	131.0	129.98	106.78	100.54	109.02	113.74	113.13	131.18	144.07
JPY/THB	End of Period	3.10	3.11	3.20	2.52	2.67	2.46	2.75	2.87	2.76
	Average	3.10	3.23	2.70	2.54	2.59	2.64	2.75	2.75	2.96
JPY/100IDR	End of Period	0.9	0.85	0.98	0.82	0.91	0.88	0.96	1.03	0.86
	Average	0.9	0.98	0.88	0.85	0.91	0.94	0.96	0.96	1.01
JPY/BRL	End of Period	43.4	43.40	46.52	38.24	45.12	41.65	51.05	52.47	42.61
	Average	44.0	45.34	41.19	39.76	46.52	49.40	49.65	49.61	50.82
JPY/RMB	End of Period	16.0	15.98	15.14	12.32	13.05	12.00	12.68	13.69	14.48
	Average	16.0	16.10	13.18	12.52	12.36	12.35	12.78	13.60	14.63

5. Number of Employees

	FY ending	6 Months		6 Months		6 Months			
	Mar/14	ended	FY ended	ended	FY ended	ended	FY ended	FY ended	FY ended
	(projected)	Sept/13	Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10	Mar/09
Parent Company			3,343	3,355	3,300		3,310	3,755	3,733
(including expatriates)			4,211	4,222	4,195		4,186	4,175	4,181
Consolidated Basis			27,518	28,476	28,245		28,084	27,215	26,869

6. Interest-bearing Debts (in millions of JPY)

	FY ending	6 Months		6 Months		6 Months			
	Mar/14	ended	FY ended	ended	FY ended	ended	FY ended	FY ended	FY ended
	(projected)	Sept/13	Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10	Mar/09
Short-term borrowings and debt		50,468	36,764	36,989	23,423	21,031	22,407	31,529	30,036
Commercial paper		20,000	-	-	-	-	-	-	-
Bonds		34,993	49,992	49,991	69,990	69,990	69,989	69,988	84,987
Long-term debt		30,877	32,557	34,589	36,626	38,376	40,994	46,384	34,378
Total		136,338	119,314	121,570	130,040	129,398	133,391	147,902	149,402
Cash and deposits with bank		144,354	186,501	88,521	149,913	117,494	141,801	97,866	69,569
Net	/	-8,016	-67,187	33,048	-19,873	11,904	-8,410	50,035	79,832

7 Depreciation (in 100 mil of IDV)

7. Depreciation								(in i	OU MIII OI JPY)
	FY ending	6 Months		6 Months		6 Months			
	Mar/14	ended	FY ended	ended	FY ended	ended	FY ended	FY ended	FY ended
	(projected)	Sept/13	Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10	Mar/09
(1) Parent company	127	63	130	63	132	67	156	183	172
Subsidiaries	306	164	304	152	315	155	356	376	384
Adjustment	-	-2	-9	-4	-10	-5	-14	-5	-3
To	tal 433	225	425	211	437	218	498	554	552
(2) By business segment									
Domestic Food Products	97	47	103	62	129	64	137	150	160
Overseas Food Products	115	66	98	44	86	40	100	104	32
Bioscience Products & Fine Chemicals	130	64	113	51	106	57	138	182	254
Pharmaceuticals	19	11	33	16	37	18	36	37	36
Other Business	20	10	19	9	22	10	24	21	21
All Company	52	27	58	28	58	29	64	60	49
To	tal 433	225	425	211	437	218	498	554	552

<sup>\*</sup>Business Tie Ups segment is abolished since FY ending Mar/14(projected).

### 8. Capital Expenditure/Investment

(in 100 mil of JPY)

	FY ending	6 Months		6 Months		6 Months			
	Mar/14	ended	FY ended	ended	FY ended	ended	FY ended	FY ended	FY ended
	(projected)	Sept/13	Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10	Mar/09
(1) Parent company	137	53	120	57	102	32	78	106	174
Subsidiaries	423	169	502	189	472	177	394	336	413
Adjustment	-	-3	-6	-3	-6	4	-13	-0	-4
Total	560	219	616	244	568	213	458	441	583
(2) By business segment									
Domestic Food Products	104	37	117	64	123	34	108	101	151
Overseas Food Products	186	65	235	96	240	98	173	134	65
Bioscience Products & Fine Chemicals	159	73	163	57	124	52	101	115	278
Pharmaceuticals	23	6	35	8	32	11	30	37	33
Other Business	32	13	18	5	20	9	17	22	12
All Company	56	25	48	13	28	9	29	33	45
Total	560	219	616	244	568	213	458	441	583

<sup>\*</sup>Business Tie Ups segment is abolished since FY ending Mar/14(projected).

9 R&D Evnenditure (in 100 mil of IDV)

J. Nab Expenditure								(111	100 11111 01 31 1)
	FY ending	6 Months		6 Months		6 Months			
	Mar/14	ended	FY ended	ended	FY ended	ended	FY ended	FY ended	FY ended
	(projected)	Sept/13	Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10	Mar/09
(1) Parent company	264	122	239	122	245	125	270	298	280
Subsidiaries	84	37	87	48	104	48	99	59	58
Tota	348	159	326	170	348	173	369	356	338
(2) By business segment									
Domestic Food Products	31	14	37	22	47	24	60	64	61
Overseas Food Products	31	14	28	14	30	15	28	22	4
Bioscience Products & Fine Chemicals	83	37	76	36	76	38	87	100	117
Pharmaceuticals	92	40	95	48	114	52	112	97	96
Other Business	9	3	7	4	8	4	12	0	0
All Company	102	51	84	46	73	40	72	73	60
Tota	348	159	326	170	348	173	369	356	338

<sup>\*</sup>Business Tie Ups segment is abolished since FY ending Mar/14(projected).

<sup>\*</sup>Change of product classification: Medical & Functional foods in Pharmaceuticals from Pharmaceuticals to Other Business since FY ending Mar/14(projected).

<sup>\*</sup>Change of product classification:Umami seasonings for processed food mfrs.
: from Bio science Products & Fine Chemicals to Overseas Food Products since FY ended Mar/11.

<sup>\*</sup>Figures for previous periods have not been restated to reflect segment changes

<sup>\*</sup>Change of product classification: Medical & Functional foods in Pharmaceuticals : from Pharmaceuticals to Other Business since FY ending Mar/14(projected). \*Change of product classification:Umami seasonings for processed food mfrs.

from Bio science Products & Fine Chemicals to Overseas Food Products since FY ended Mar/11.

<sup>\*</sup>Figures for previous periods have not been restated to reflect segment changes.

<sup>\*</sup>Change of product classification: Medical & Functional foods in Pharmaceuticals

from Pharmaceuticals to Other Business since FY ending Mar/14(projected).

<sup>\*</sup>Change of product classification:Umami seasonings for processed food mfrs.
: from Bio science Products & Fine Chemicals to Overseas Food Products since FY ended Mar/11.

<sup>\*</sup>Figures for previous periods have not been restated to reflect segment changes.

10. Selling, G&A Expenses								(in m	nillions of JPY)
	FY ending	6 Months		6 Months		6 Months			
	Mar/14	ended	FY ended	ended	FY ended	ended	FY ended	FY ended	FY ended
	(projected)	Sept/13	Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10	Mar/09
(1) Selling Expense	<u> </u>		-			1	-	-	-
Transportation		14,356	31,423	17,173	34,265	17,871	33,450	31,675	34,246
Advertisement		14,717	32,700	16,252	32,571	15,824	33,628	34,213	31,276
Sales commission		19,246	53,681	32,439	61,331	30,938	62,089	58,560	59,974
Miscellaneous		11,531	22,552	11,538	22,257	10,866	23,809	23,606	21,814
Total		59,853	140,357	77,404	150,425	75,502	152,978	148,055	147,311
(2) General and Administrative Expenses									
Salaries		22,313	43,955	22,624	45,238	22,289	42,981	42,847	41,580
Bonuses and other allowances		8,601	17,421	9,052	18,888	9,270	17,898	16,938	15,625
Periodic pension and severance cost	7	2,542	6,561	3,086	8,971	4,021	9,484	8,365	7,022
Depreciation expense	/	4,523	9,948	4,826	10,395	4,888	10,543	9,583	8,400
Amortization of goodwill*	1,544	807	2,265	1,707	4,503	2,251	4,505	5,000	5,497
Other		45,283	92,594	48,710	92,781	46,006	95,211	90,472	90,982
Total		84,070	172,747	90,005	180,777	88,727	180,625	173,208	169,108
Total Selling, G&A expenses	299,500	143,923	313,104	167,410	331,203	164,229	333,604	321,264	316,420

11. Non-Operating Income & Loss (in millions of JPY) FY ending 6 Months 6 Months 6 Months Mar/14 ended FY ended ended FY ended ended FY ended FY ended FY ended Mar/11 Mar/10 (projected) Sept/13 Mar/13 Sept/12 Mar/12 Sept/11 Mar/09 (1) Non-Operating Income Interest income 1,857 1,847 974 2,401 1,232 939 2,990 1,046 953 2,524 1,012 3,461 2,639 2,656 10,931 1,044 3,058 666 1,311 562 1,048 Dividend income Equity in earnings of affiliates
Exchange gains 1,865 3,983 9,944 1,311 4,137 2,263 7,487 2,250 7,411 2,706 7,230 3,985 1,494 Total 5,850 4,010 (2) Non-Operating Expense Interest expense Exchange losses Other 1,080 1,931 1,021 2,167 1,087 2,440 3,468 4,774 205 3,639 12,429 4,927 22,131 3,876 7,344 2,077 745 1,985 4,152 1,385 1,404 Total 2,484 1,767 2,472 4,009 6,286

12. Extraordinary Items								(in m	nillions of JPY)
	FY ending Mar/14 (projected)	6 Months ended Sept/13	FY ended Mar/13	6 Months ended Sept/12	FY ended Mar/12	6 Months ended Sept/11	FY ended Mar/11	FY ended Mar/10	FY ended Mar/09
(1) Extraordinary Gains	(projected)	ОСРОТО	Wan 10	ОСРЕ 12	Widi, 12	ОСРЕТТ	IVIAI, I I	Wali, 10	IVIGI, CO
Gain on prior period adjustment	//	-	-	-	-	-	-	1,322	-
Gain on sales of fixed assets	/ 1	-	-	-	-	-	-	-	799
Gain on sales of investment securities	/ 1	-	-	-	554	332	912	-	23
Gain on sales of investments in affiliates		2,267	18,201	_	-	_	-	-	437
Reversal of accrued expense on contract alteration		-	-	_	-	_	-	1,437	-
Cancellation money		-	-	-	-	-	-	-	560
Insurance income		1,190	1,800		6,012	182	182		
Gain on transfer of benefit obligation relating to employees' pension fund		-	27,752	27,752	-		-	-	-
Other	<del>       </del>	250	1,837	1,455	521	182	2,126	609	2,868
Total	<del>                                     </del>	3,708	49,141	29,208		515	3,220	3,368	
(2) Extraordinary Losses	/ /	5,. 55	,	20,200	.,000	0.0	0,220	0,000	.,000
Loss on disposal of fixed assets	<del>     </del>	662	2,951	-	3,320	-	0	4,536	3,401
Impairment losses	/ 1	-	14,562	-	1,106		8,503	14,325	
Loss on sales of fixed assets		-	-	-	- '	723	-	-	-
Loss on devaluation of securities		-	2,346	2,704	607	9	7,416	-	799
Retirement benefit expenses		-	-	-	-	-	-	-	343
Loss on devaluation of investments in affiliates		-	-	_	-	-	-	-	257
Loss on liquidation of affiliates		702	-	-	-	-	-	-	-
Loss from natural disaster		-	-	-	3,759	1,313	3,231	-	-
Other		670	7,966	1,755	2,121	1,406	6,123	7,337	3,718
Total	/	2,036	25,481	4,459	10,915	3,452	25,275	26,198	27,359

### 13. Information by Business segment

Business Segment from FY ended Mar/14 (Post-reclassification of products\*)

(in millions of JPY)

Buomicoo cogment nomi i i chaca man i + (i c	ot rooidoomoation c	producto j					(	
	FY ending	6 Months		6 Months		6 Months		
	Mar/14	ended	FY ended	ended	FY ended	ended	FY ended	FY ended
	(projected)	Sept/13	Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10
Domestic Food Products								
Sales to external customers	340,500	161,177	391,554	221,157	428,996		427,707	425,749
Y/Y %	87%	73%	91%	-	100%	#DIV/0!	100%	-
Operating income	27,600	10,961	32,641	17,279	31,705		26,506	24,311
Y/Y %	85%	63%	103%	-	120%	#DIV/0!	109%	-
Overseas Food Products								
Sales to external customers	317,200	144,501	245,397	114,832	230,541		231,990	214,613
Y/Y %	129%	126%	106%	-	99%	#DIV/0!	108%	-
Operating income	26,300	12,877	20,703	10,249	21,545		26,837	25,465
Y/Y %	127%	126%	96%	-	80%	#DIV/0!	105%	-
Bioscience Products & Fine Chemicals								
Sales to external customers	238,200	111,816	204,206	96,922	198,021		198,291	193,553
Y/Y %	117%	115%	103%	-	100%	#DIV/0!	102%	-
Operating income	9,400	3,923	14,368	7,268	12,159		8,685	5,252
Y/Y %	65%	54%	118%	-	140%	#DIV/0!	165%	-
Pharmaceuticals								
Sales to external customers	51,800	27,899	71,450	35,926	77,922		82,645	82,594
Y/Y %	72%	78%	92%	-	94%	#DIV/0!	100%	-
Operating income	4,300	1,546	3,194	1,801	6,488		7,940	12,353
Y/Y %	135%	86%	49%	-	82%	#DIV/0!	64%	-
Other Business								
Sales to external customers	84,300	41,690	72,358	37,082	71,727		74,579	66,152
Y/Y %	117%	112%	101%	-	96%	#DIV/0!	113%	-
Operating income	400	213	324	289	686		-595	-3,348
Y/Y %	123%	74%	47%	-	-115%	#DIV/0!	18%	-
Consolidated, Total								
Net Sales	1,032,000	487,084	984,967	505,921	1,007,208		1,015,213	982,663
Y/Y %	105%	96%	98%	-	99%	#DIV/0!	103%	-
Operating income	68,000	29,521	71,232	36,887	72,584		69,374	64,034
Y/Y %	95%	80%	98%	-	105%	#DIV/0!	108%	-

<sup>\*</sup> Change of product classification:

<sup>•</sup>Domestic Food Products: Previous years' figures for Kellogg's products restated as net sales less cost of sales.

 $<sup>\</sup>hbox{\bf \cdot} \hbox{Medical foods: Moved from Pharmaceuticals to Other Business}$ 

<sup>(</sup>figures for previous years not restated).

<sup>•</sup>Business Tie-Ups: Moved to Other Business; figures for previous years restated as net sales less cost of sales.

<sup>\*</sup> Pharmaceuticals: Sales decreased due to transfer of Infusions and dialysis business in July 2013.

### Business Segment until FY ended Mar/13 (Pre-reclassification of products)

Domestic Food Products Sales to external customers Y/Y % Operating income Y/Y % Overseas Food Products
Sales to external customers
Y/Y % Operating income Y/Y % Bioscience Products & Fine Chemicals Sales to external customers Y/Y % Operating income Y/Y % Pharmaceuticals Sales to external customers Y/Y % Operating income Y/Y %
Business Tie-Ups Sales to external customers Y/Y % Operating income Y/Y % Other Business Sales to external customers Y/Y % Operating income Y/Y % Consolidated, Total Net Sales Y/Y % Operating income Y/Y %

					(in m	nillions of JPY)
FY ended	6 Months ended	FY ended	6 Months ended	FY ended	FY ended	FY ended
					Mar/10	
Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10	Mar/09
401,183	226,515	438,423	221,539	437,838	436,021	453,436
92%	102%	100%	99%	100%	96%	-
32,641	17,279	31,705	18,327	26,506	24,311	14,407
103%	94%	120%	126%	109%	169%	-
245,397	114,832	230,541	114,976	231,990	214,613	199,038
106%	100%	99%	100%	108%	108%	199,036
20,703	10,249	21,545	11,591	26,837	25,465	11,197
96%	88%	80%	77%	105%	227%	-
204,206	96,922	198,021	98,630 98%	198,291	193,553	199,734
103%		98% 100%		102%	97%	-
14,368	7,268	12,159	6,309	8,685	5,252	
118%	115%	140%	96%	165%	104%	-
71,450	35,926	77,922	41,344	82,645	82,594	85,751
92%	87%	94%	99%	100%	96%	-
3,194	1,801	6,488	5,494	7,940	12,353	14,526
49%	33%	82%	107%	64%	85%	-
400.070	22.252	400.000	00.000	101 ==1	100 105	400 500
180,079 98%	88,650 98%	182,830 99%	90,808 96%	184,574 102%	180,435 95%	189,520
1,585	98% 777	1,618	96% 810	1,594	1,648	1,784
98%	96%	101%	98%	97%	92%	1,704
3070	3070	10170	3070	31 70	3270	
70,126	36,011	69,574	36,811	72,354	63,657	62,890
101%	98%	96%	94%	114%	101%	- '
-1,261	-487	-931	61	-2,190	-4,996	-6,160
135%	-	43%	-	44%	81%	-
4 470 440	F00 000	4 407 040	004.440	4 007 005	4 470 070	4 400 074
1,172,442	598,860	1,197,313	604,110	1,207,695	1,170,876	1,190,371
98%	99%	99%	98%	103%	98%	98%
71,232 98%	36,887 87%	72,584 105%	42,594 102%	69,374 108%	64,034 157%	40,827 67%
90%	0170	105%	102%	100%	157 70	0770

### 14. Information by Geographic segment

Geographic Segment from FY ended Mar/14 (Post-reclassification of products\*)

(in millions of JPY)

		p	,				(	
	FY ending	6 Months		6 Months		6 Months		
	Mar/14	ended	FY ended	ended	FY ended	ended	FY ended	FY ended
	(projected)	Sept/13	Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10
Japan								
Sales to external customers	525,700	253,350	577,458	315,998	624,808		638,329	624,243
Y/Y %	91%	80%	92%	-	98%	#DIV/0!	102%	96%
Operating income	32,000	13,551	34,350	18,488	35,555		32,269	30,312
Y/Y %	93%	73%	97%	-	110%	#DIV/0!	106%	123%
Asia								
Sales to external customers	255,300	115,665	194,846	91,963	177,977		174,836	159,795
Y/Y %	131%	126%	109%	-	102%	#DIV/0!	109%	106%
Operating income	28,000	13,508	22,105	11,490	21,585		21,226	21,734
Y/Y %	127%	118%	102%	-	102%	#DIV/0!	98%	199%
Americas								
Sales to external customers	146,000	68,078	117,483	55,840	114,084		113,556	105,437
Y/Y %	124%	122%	103%	-	100%	#DIV/0!	108%	99%
Operating income	6,400	2,750	9,285	4,711	8,888		7,551	5,875
Y/Y %	69%	58%	104%	-	118%	#DIV/0!	129%	102%
Europe								
Sales to external customers	105,000	49,990	95,178	42,119	90,338		88,491	93,187
Y/Y %	110%	119%	105%	-	102%	#DIV/0!	95%	104%
Operating income	1,600	-289	5,491	2,197	6,554		8,327	6,112
Y/Y %	29%	-13%	84%	-	79%	#DIV/0!	136%	-
Consolidated, Total								
Sales to external customers	1,032,000	487,084	984,967	505,921	1,007,208	0	1,015,213	982,663
Y/Y %	105%		98%	- '	99%		103%	
Operating income	68,000	29,521	71,232	36,887	72,584		69,374	64,034
Y/Y %	95%		98%	-	105%		108%	

Geographic Segment until FY ended Mar/13 (Pre-reclassification of products\*\*)

(in millions of JPY)

Japan**
Sales to external customers Y/Y %
Operating income Y/Y %
Asia
Sales to external customers Y/Y %
Operating income Y/Y %
Americas
Sales to external customers Y/Y %
Operating income Y/Y %
Europe
Sales to external customers Y/Y %
Operating income Y/Y %
Consolidated, Total
Sales to external customers
Y/Y %
Operating income Y/Y %

	6 Months		6 Months				
FY ended	ended	FY ended	ended FY ended		FY ended	FY ended	
Mar/13	Sept/12	Mar/12	Sept/11	Mar/11	Mar/10	Mar/09	
	·		,				
764,934	408,936	814,912	413,106	830,810	812,456	843,395	
94%	99%	98%	96%	102%	96%	101%	
34,350	18,488	35,555	23,760	32,269	30,312	24,667	
97%	78%	110%	121%	106%	123%	1	
194,846	91,963			174,836		151,063	
109%	103%	102%	103%	109%	106%	95%	
22,105	11,490			21,226	21,734	10,922	
102%	100%	102%	90%	98%	199%	-	
117,483	55,840				105,437	106,511	
103%	97%	100%	101%	108%	99%	97%	
9,285	4,711	8,888		7,551	5,875	5,779	
104%	125%	118%	77%	129%	102%	-	
95,178	42,119				93,187	89,400	
105%	96%	102%	101%	95%	104%	78%	
5,491	2,197	6,554	3,583	8,327	6,112	-542	
84%	61%	79%	79%	136%	-	-	
1,172,442	598,860				1,170,876	1,190,371	
98%	99%	99%	98%	103%	98%	98%	
71,232	36,887	72,584	42,594	69,374	64,034	40,827	
98%	87%	105%	102%	108%	157%	67%	